Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer

Andrew Rankin, Samuel J. Klempner, Rachel Erlich, James X. Sun, Axel Grothey, Marwan Fakih, Thomas J. George, Jeeyun Lee, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Introduction. A KRAS mutation represented the first genomic biomarker to predict lack of benefit from anti-epidermal growth factor receptor (EGFR) antibody therapy in advanced colorectal cancer (CRC). Expanded RAS testing has further refined the treatment approach, but understanding of genomic alterations underlying primary and acquired resistance is limited and further study is needed. Materials and Methods.We prospectively analyzed 4,422 clinical samples from patients with advanced CRC, using hybridcapture based comprehensive genomic profiling (CGP) at the request of the individual treating physicians. Comparison with priormolecular testing results, when available,was performed to assess concordance. Results.We identified a RAS/RAF pathway mutation or amplification in 62% of cases, including samples harboring KRAS mutations outside of the codon 12/13 hotspot region in 6.4% of cases. Among cases with KRAS non-codon 12/13 alterations for which prior test results were available, 79 of 90 (88%) were not identified by focused testing. Of 1,644 RAS/RAF wild-type cases analyzed by CGP, 31% harbored a genomic alteration (GA) associated with resistance to anti- EGFRtherapy in advanced CRC including mutations in PIK3CA, PTEN, EGFR, and ERBB2.We also identified other targetable GA, including novel kinase fusions, receptor tyrosine kinase amplification, activating point mutations, as well as microsatellite instability. Conclusion. Extended genomic profiling reliably detects alterations associated with lack of benefit to anti-EGFR therapy in advanced CRC, while simultaneously identifying alterations potentially important in guiding treatment. The use of CGP during the course of clinical care allows for the refined selection of appropriate targeted therapies and clinical trials, increasing the chance of clinical benefit and avoiding therapeutic futility.

Original languageEnglish (US)
Pages (from-to)1306-1314
Number of pages9
JournalOncologist
Volume21
Issue number11
DOIs
StatePublished - Nov 2016

Keywords

  • Biomarker
  • Cetuximab
  • Colon cancer
  • Epidermal growth factor receptor
  • Genomic profiling
  • KRAS

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Rankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., & Schrock, A. B. (2016). Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer. Oncologist, 21(11), 1306-1314. https://doi.org/10.1634/theoncologist.2016-0148